Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
Adobe
By Elaine Chen
June 7, 2026
National Biotech Reporter
Elaine Chen
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
Nearly 1 in 5 patients quit Boehringer and Zealand’s obesity shot over side effects
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out…
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on…
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other…
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could…
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And…
On secondary endpoints that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk…
